This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Acetylcysteine

Authoring team

N-acetylcysteine is a sulphydryl compound that is used in the treatment of paracetamol poisoning.

  • assists in the conjugation of toxic metabolites of paracetamol and so helps to prevent hepatic necrosis.
  • it may produce an anaphylactic reaction
  • mainstay of therapy for acetaminophen toxicity (paracetamol poisoning)

The primary role of N-acetylcysteine is associated with its antioxidant and anti-inflammatory activity, which favours the maintenance of a cellular redox imbalance (1)

  • for this reason, its therapeutic potential concerns a series of diseases that link oxidative stress to its etiology and progression

N-acetylcysteine is also used as a mucolytic compound.

  • approved for use in conditions with abnormal, viscid or inspissated mucous secretions such as (2)
    • pneumonia
    • bronchitis
    • tracheobronchitis
    • cystic fibrosis
    • tracheostomy patients
    • postoperative pulmonary complications
    • posttraumatic chest conditions
    • before diagnostic bronchoscopy to help with mucous plugging

Reference:

  • Tenório MCDS, Graciliano NG, Moura FA, Oliveira ACM, Goulart MOF. N-Acetylcysteine (NAC): Impacts on Human Health. Antioxidants (Basel). 2021 Jun 16;10(6):967. doi: 10.3390/antiox10060967.
  • Ershad M, Naji A, Vearrier D. N-Acetylcysteine. In: StatPearls. StatPearls Publishing, Treasure Island (FL); 2023. PMID: 30725868.

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.